Health and Healthcare
5864 Articles
Johnson & Johnson is looking to save some money over the next few years and as a result it is…
UnitedHealth Group released a better-than-expected fourth-quarter earnings report before the markets opened on Tuesday.
These biotech companies stood out from the rest with big moves over the course of the past week.
Merrill Lynch sees some stabilization in the hepatitis C market in 2016 that might allow Gilead Sciences to stay above…
Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.
These companies are well along in clinical trials and some are close to presenting Phase 3 results. Sticking with industry…
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks…
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech…
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th…
Celgene Corp. (NASDAQ: CELG) sank in Monday's session after providing a business update that was largely in line with analyst…
Anavex Life Sciences was one of the stocks helping to prop up the market in Monday’s session.
Clearside Biomedical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
A new RBC report focuses on top biotech stocks with key data readouts coming in 2016. These three seem to…
Affymetrix was absolutely soaring early on Monday on word that it will be acquired. Thermo Fisher Scientific is the buyer.
Athersys has announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy…
Our top personal finance-related articles today. Your wallet will thank you later.